Abstract
This study aims to evaluate the value of perfusion MRI as a predictive/prognostic biomarker and a pharmacodynamic biomarker in patients with recurrent glioma treated with a bevacizumab-based regimen. We identified thirteen literature reports that investigated dynamic susceptibility-contrast (DSC) MRI or dynamic contrast-enhanced (DCE) MRI for predicting the patient outcome and analyzing the anti-angiogenic effect of bevacizumab by performing a systematic search of MEDLINE and EMBASE. The relative cerebral volume (rCBV) of DSC-MRI is currently the most common perfusion MRI parameter used as a predictive/prognostic biomarker. Pooled hazard ratios between responders and non-responders, as determined by rCBV, were 0.46 (95 % CI 0.28–0.76) for progression-free survival from five articles with a total 226 patients and 0.47 (95 % CI 0.29–0.76) for overall survival from six articles with a total 247 patients, and thus indicating that rCBV is helpful for predicting disease progression and the eventual outcome after treatment. Regarding the pharmacodynamic value of perfusion MRI parameters derived from either DSC-MRI or DCE-MRI, most perfusion MRI parameters (rCBV, Ktrans, CBVmax, Kpsmax, fpv, Ve and Kep) demonstrated a consistent decrease on the follow-up MRI after treatment, indicating that perfusion MRI may be helpful for evaluating the anti-angiogenic effect of a bevacizumab-based treatment regimen. However, the lack of standardization of imaging acquisition and analysis techniques for various perfusion MRI parameters needs to be resolved in the future. Despite these unsolved issues, the current evidence favoring the use of perfusion MRI as a predictive/prognostic or pharmacodynamic biomarker should be considered in patients with glioma treated using a bevacizumab-based regimen.
Similar content being viewed by others
References
Aquino D, Di Stefano AL, Scotti A, Cuppini L, Anghileri E, Finocchiaro G, Bruzzone MG, Eoli M (2014) Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS ONE 9(3):e90535. doi:10.1371/journal.pone.0090535
Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28(18):3069–3075. doi:10.1200/jco.2009.26.8789
Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13(10):1143–1150. doi:10.1093/neuonc/nor091
Lavini C, Verhoeff JJ, Majoie CB, Stalpers LJ, Richel DJ, Maas M (2011) Model-based, semiquantitative and time intensity curve shape analysis of dynamic contrast-enhanced MRI: a comparison in patients undergoing antiangiogenic treatment for recurrent glioma. J Magn Reson Imaging: JMRI 34(6):1303–1312. doi:10.1002/jmri.22742
Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL (2015) Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro-oncology 17(8):1148–1156. doi:10.1093/neuonc/nou364
Zukotynski KA, Fahey FH, Vajapeyam S, Ng SS, Kocak M, Gururangan S, Kun LE, Poussaint TY (2013) Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucli Med 54(8):1237–1243. doi:10.2967/jnumed.112.115782
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A (2015) Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw 13(10):1191–1202
Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11(3):336–344. doi:10.1007/s11910-011-0179-x
O’Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9(3):167–177. doi:10.1038/nrclinonc.2012.2
Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191(1):41–51. doi:10.1148/radiology.191.1.8134596
Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27(4):859–867
Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238(2):658–667. doi:10.1148/radiol.2382042180
Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE 2nd, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP (2013) Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys 86(5):873–879. doi:10.1016/j.ijrobp.2013.04.029
Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM (2015) MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 122(3):497–505. doi:10.1007/s11060-015-1755-8
Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A (2015) Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro-oncology 17(8):1139–1147. doi:10.1093/neuonc/nov028
Kickingereder P, Wiestler B, Graf M, Heiland S, Schlemmer HP, Wick W, Wick A, Bendszus M, Radbruch A (2015) Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. J Neurooncol 121(2):373–380. doi:10.1007/s11060-014-1644-6
Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM (2014) Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 14:31. doi:10.1186/s40644-014-0031-z
Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG (2014) Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro-oncology 16(6):880–888. doi:10.1093/neuonc/not216
Takano S, Kimu H, Tsuda K, Osuka S, Nakai K, Yamamoto T, Ishikawa E, Akutsu H, Matsuda M, Matsumura A (2013) Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. Acta Neurochir Suppl 118:185–189. doi:10.1007/978-3-7091-1434-6_34
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clin Res ed) 339:b2535. doi:10.1136/bmj.b2535
Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008) Prognostic versus predictive value of biomarkers in oncology. Eur j Cancer (Oxf Engl 1990) 44(7):946–953. doi:10.1016/j.ejca.2008.03.006
Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9(5):e1001216. doi:10.1371/journal.pmed.1001216
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin res ed) 327(7414):557–560. doi:10.1136/bmj.327.7414.557
Sullivan DC, Obuchowski NA, Kessler LG, Raunig DL, Gatsonis C, Huang EP, Kondratovich M, McShane LM, Reeves AP, Barboriak DP, Guimaraes AR, Wahl RL (2015) Metrology standards for quantitative imaging biomarkers. Radiology 277(3):813–825. doi:10.1148/radiol.2015142202
Committee DMT (2014) DCE MRI quantification profile, quantitative imaging, biomarkers alliance. Version 1.0. Reviewed Draft. QIBA, July 1, 2012
Neagu MR, Huang RY, Reardon DA, Wen PY (2015) How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol 17(4):343. doi:10.1007/s11940-015-0343-8
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495. doi:10.1016/j.ijrobp.2009.12.061
Acknowledgments
None
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Kim KW has received research a Grant (No. 2014-0351) from the Asan Institute for Life Sciences of Asan Medical Center and a Grant (No. 2014R1A1A1006823) from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning. The other authors have no conflict of interest.
Informed consent
For this type of study formal consent is not required.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Sang Hyun Choi and Seung Chai Jung have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Choi, S.H., Jung, S.C., Kim, K.W. et al. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neurooncol 128, 185–194 (2016). https://doi.org/10.1007/s11060-016-2102-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-016-2102-4